Early results suggested that the peptide might have contributed to an increase in body mass and possibly raised the bone mineral content (BMC) in the tibia and vertebrae, as indicated by DEXA measurements, compared to the control group
Minerva Gastroenterol Dietol
Furthermore, by preserving lean muscle mass and preventing age-related muscle loss, IGF-1 LR3 may support a stronger and healthier physique
Sermorelin's FDA Journey: Approved, Discontinued, and Compounded Sermorelin acetate (Geref) was FDA-approved in 1997 for pediatric GHD 1 and in 1990 for diagnostic use.26 The manufacturer discontinued Geref in 2008 due to "manufacturing difficulties," not safety or efficacy concerns.12 In 2013, the FDA confirmed it wasn't withdrawn for safety/effectiveness, allowing for potential generic approvals.12 Currently, Sermorelin is primarily available as a compounded medication 3, which is permitted but not individually FDA-approved like mass-produced drugs.22 5.2
In the three human studies completed, the safety profile has been promising